Program
Pegloticase
Also written as “pegloticase”, “Pegloticase with MTX” and “Puricase”.
Its studies are mostly in Gout · Renal Insufficiency, Chronic, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 81 open or running | phase 4since Aug 9, 2018 | Aug 9, 2018 | Jun 18, 2028phase 3 · NCT07388498 |
| Savient Pharmaceuticals | 50 open or running | phase 3since May 10, 2006 | Mar 24, 2004 | none ahead |
| Ampel BioSolutions | 10 open or running | phase 2since Oct 30, 2015 | Oct 30, 2015 | none ahead |
Also a collaborator on its studies: ind-2-results-llc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2004First study: phase 2 study in GoutNew to Savient PharmaceuticalsSavient Pharmaceuticals · NCT00080210 · 40 enrolled · United States
- May 10, 2006Phase 3 study in GoutSavient Pharmaceuticals · NCT00325195 · 225 enrolled · United States, Canada, Mexico
- May 6, 2008Phase 3 study in GoutSavient Pharmaceuticals · NCT00675103 · 7 enrolled · United States
- Oct 27, 2008Phase 3 study in GoutSavient Pharmaceuticals · NCT01356498 · 151 enrolled · United States
- Nov 29, 2012Phase 1 study in Renal Insufficiency, ChronicSavient Pharmaceuticals · NCT01739660 · 12 enrolled · United States
- Oct 30, 2015Ampel BioSolutions's first study: phase 2 study in GoutNew to Ampel BioSolutionsAmpel BioSolutions · NCT02598596 · 132 enrolled · United States
- Aug 9, 2018Amgen's first study: phase 4 study in GoutNew to AmgenAmgen · NCT03635957 · 14 enrolled · United States
- Jun 19, 2019Phase 4 study in GoutAmgen · NCT03994731 · 152 enrolled · United States
- Sep 11, 2019Phase 4 study in Uncontrolled GoutAmgen · NCT04087720 · 20 enrolled · United States
- Aug 11, 2020Phase 4 study in GoutAmgen · NCT04511702 · 191 enrolled · United States
- Feb 12, 20212 phase 4 studies in GoutAmgen · NCT04762498, NCT04772313
- Jan 19, 2024Phase 4 study in GoutAmgen · NCT06229145 · 306 enrolled · United States
- Jan 29, 2026Phase 3 study in Uncontrolled GoutAmgen · NCT07388498 · 270 planned · United States, Puerto Rico
Ahead
- Jun 18, 2028Primary completion: phase 3 study in Uncontrolled GoutAmgen · NCT07388498
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07388498Uncontrolled Gout · United States, Puerto Rico | 3 | Recruiting | Amgen | Jun 18, 2028 | 270 |
| NCT06229145Gout · United States | 4 | Completed | Amgen | Jul 30, 2025 | 306 |
| NCT04772313Gout · United States | 4 | Completed | Amgen | Aug 23, 2022 | 11 |
| NCT04762498Gout · United States | 4 | Completed | Amgen | May 18, 2023 | 54 |
| NCT04511702Gout · United States | 4 | Completed | Amgen | Jan 18, 2024 | 191 |
| NCT04087720Uncontrolled Gout · United States | 4 | Completed | Amgen | Jul 6, 2021 | 20 |
| NCT03994731Gout · United States | 4 | Completed | Amgen | Mar 17, 2021 | 152 |
| NCT03635957Gout · United States | 4 | Completed | Amgen | Oct 23, 2019 | 14 |
| NCT02598596Gout · United States | 2 | Completed | Ampel BioSolutions | Apr 13, 2020 | 132 |
| NCT01739660Renal Insufficiency, Chronic · United States | 1 | Completed | Savient Pharmaceuticals | Apr 2013 | 12 |
| NCT01356498Gout · United States | 3 | Completed | Savient Pharmaceuticals | Jan 2010 | 151 |
| NCT00675103Gout · United States | 3 | Completed | Savient Pharmaceuticals | Jan 2009 | 7 |
| NCT00325195Gout · United States, Canada, Mexico | 3 | Completed | Savient Pharmaceuticals | Oct 2007 | 225 |
| NCT00080210Gout · United States | 2 | Completed | Savient Pharmaceuticals | 40 |
How it is read
Names in the registry
- “Pegloticase”, 9 entries
- “pegloticase”, 2 entries
- “Pegloticase with MTX”, 1 entry
- “Puricase”, 1 entry
- “pegloticase 8 mg i.v.”, 1 entry
Conditions, from the studies’ own filings
- Gout, 13 studies
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.